CONTX logo

ContextVision AB (publ) Stock Price

OB:CONTX Community·NOK 257.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

CONTX Share Price Performance

NOK 0
-4.90 (-100.00%)
NOK 3.30
Fair Value
NOK 0
-4.90 (-100.00%)
Price NOK 0

CONTX Community Narratives

·
Fair Value NOK 3.3 8.8% overvalued intrinsic discount

AI Diagnostic Solutions Will Transform Medical Imaging Globally

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
NOK 3.3
8.8% overvalued intrinsic discount
Revenue
2.06% p.a.
Profit Margin
13.79%
Future PE
17.4x
Price in 2029
NOK 4.08

Trending Discussion

Updated Narratives

CONTX logo

CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI

Fair Value: NOK 3.3 8.8% overvalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
0 Rewards

ContextVision AB (publ) Key Details

SEK 113.5m

Revenue

SEK 64.9m

Cost of Revenue

SEK 48.6m

Gross Profit

SEK 43.9m

Other Expenses

SEK 4.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 27, 2026
0.063
42.82%
4.16%
0%
View Full Analysis

About CONTX

Founded
1989
Employees
43
CEO
Gerald Potzsch
WebsiteView website
www.contextvision.se

ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally. The company offers image quality solutions for ultrasound, as well as its Rivent platform comprising Rivent, a 2D image enhancement; Rivent Plus, a premium 2D image enhancement product; Rivent 3D, a solution for improving image quality of 3D ultrasound; and Rivent Mobile, a 2D image enhancement for handheld devices for diagnostics in various fields, including radiology, cardiology, women’s health, veterinary medicine, and point of-care applications. It also provides Altumira platform, which features scatter correction and improves radiography by enabling radiation dose reduction while enhancing image quality, such as Altumira for static applications; and Altumira Plus for dynamic applications. In addition, the company offers image quality solutions for MRI including GOPView MRI2Plus for the requirements of each application, sequence type, and protocol; and implementation projects, software updates, and upgrades and product support services. It has a strategic clinical development partnership with the University of Washington to identify a multiparametric biomarker for the screening and staging of the liver disease MASLD; and research partnership with AMRA Medical. ContextVision AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden.

Recent CONTX News & Updates

Recent updates

No updates